Safety, Immunologic Effects and Clinical Response in a Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells in Patients with Treatment Refractory Systemic Lupus Erythematosus
Diane Kamen, Caroline Wallace, Zihai Li, Megan Wyatt, Crystal Paulos, Chungwen Wei, Hongjun Wang, Inaki Sanz, Bethany J Wolf, Paul J Nietert, Angela Robinson, Gary Gilkeson
doi: https://doi.org/10.1101/2022.03.31.22273106
Diane Kamen
1Department of Medicine, Division of Rheumatology, Medical University of South Carolina
Caroline Wallace
1Department of Medicine, Division of Rheumatology, Medical University of South Carolina
Zihai Li
2Department of Medicine, Division of Hematology/Oncology, Ohio State Wexner Medical Center
Megan Wyatt
3Department of Surgery, Emory University Medical Center
Crystal Paulos
3Department of Surgery, Emory University Medical Center
Chungwen Wei
4Department of Medicine, Rochester University Medical Center
Hongjun Wang
5Department of Surgery, Medical University of South Carolina
Inaki Sanz
6Department of Medicine, Division of Rheumatology, Emory University Medical Center
Bethany J Wolf
7Department of Public Health Sciences, Medical University of South Carolina
Paul J Nietert
7Department of Public Health Sciences, Medical University of South Carolina
Angela Robinson
1Department of Medicine, Division of Rheumatology, Medical University of South Carolina
Gary Gilkeson
1Department of Medicine, Division of Rheumatology, Medical University of South Carolina
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted April 03, 2022.
Safety, Immunologic Effects and Clinical Response in a Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells in Patients with Treatment Refractory Systemic Lupus Erythematosus
Diane Kamen, Caroline Wallace, Zihai Li, Megan Wyatt, Crystal Paulos, Chungwen Wei, Hongjun Wang, Inaki Sanz, Bethany J Wolf, Paul J Nietert, Angela Robinson, Gary Gilkeson
medRxiv 2022.03.31.22273106; doi: https://doi.org/10.1101/2022.03.31.22273106
Safety, Immunologic Effects and Clinical Response in a Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells in Patients with Treatment Refractory Systemic Lupus Erythematosus
Diane Kamen, Caroline Wallace, Zihai Li, Megan Wyatt, Crystal Paulos, Chungwen Wei, Hongjun Wang, Inaki Sanz, Bethany J Wolf, Paul J Nietert, Angela Robinson, Gary Gilkeson
medRxiv 2022.03.31.22273106; doi: https://doi.org/10.1101/2022.03.31.22273106
Subject Area
Subject Areas
- Addiction Medicine (324)
- Allergy and Immunology (628)
- Anesthesia (165)
- Cardiovascular Medicine (2383)
- Dermatology (207)
- Emergency Medicine (380)
- Epidemiology (11777)
- Forensic Medicine (10)
- Gastroenterology (703)
- Genetic and Genomic Medicine (3751)
- Geriatric Medicine (350)
- Health Economics (635)
- Health Informatics (2401)
- Health Policy (935)
- Hematology (341)
- HIV/AIDS (782)
- Medical Education (366)
- Medical Ethics (105)
- Nephrology (398)
- Neurology (3513)
- Nursing (198)
- Nutrition (528)
- Oncology (1825)
- Ophthalmology (538)
- Orthopedics (219)
- Otolaryngology (287)
- Pain Medicine (233)
- Palliative Medicine (66)
- Pathology (446)
- Pediatrics (1035)
- Primary Care Research (422)
- Public and Global Health (6150)
- Radiology and Imaging (1281)
- Respiratory Medicine (828)
- Rheumatology (379)
- Sports Medicine (323)
- Surgery (402)
- Toxicology (50)
- Transplantation (172)
- Urology (146)